Epigenetic Control of Hypertension by DNA Methylation: A Real Possibility

Author(s): Priscila M. João Job, Francislaine A. dos Reis Lívero, Arquimedes G. Junior*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 35 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Hypertension is a common chronic disease that particularly affects the elderly and can trigger several cardiovascular conditions. Although the treatment of hypertension has evolved in recent decades, many hypertensive patients still do not have properly controlled blood pressure. Accumulating evidence supports the hypothesis that DNA methylation plays an important role in regulating gene expression, altering the phenotype and function of the cardiovascular system. The present review highlights recent advances in research on DNA methylation in the development of hypertension. Several preclinical and clinical evidence show that methylation of different targets appears to be involved in hypertension. Studies of the involvement of DNA methylation have greatly improved our understanding of hypertension, but its use as a valid therapeutic target is still unknown. Further studies could help to bring to light the truth about gene therapy in hypertension.

Keywords: Blood pressure, cardiovascular disease, chronic disease, drug discovery, epigenomic, gene, phenotype.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 35
Year: 2021
Published on: 22 March, 2021
Page: [3722 - 3728]
Pages: 7
DOI: 10.2174/1381612827666210322141703
Price: $95

Article Metrics

PDF: 129